首页> 美国卫生研究院文献>Case Reports in Oncology >Successful Treatment of Richter Transformation with Ibrutinib in a Patient with Chronic Lymphocytic Leukemia following Allogeneic Hematopoietic Stem Cell Transplant
【2h】

Successful Treatment of Richter Transformation with Ibrutinib in a Patient with Chronic Lymphocytic Leukemia following Allogeneic Hematopoietic Stem Cell Transplant

机译:异基因造血干细胞移植后慢性淋巴细胞白血病患者用依鲁替尼成功治疗Richter转化

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Patients with chronic lymphocytic leukemia (CLL) who progress to Richter transformation (RT) have a poor prognosis. Multi-agent chemotherapy regimens do not have good response rates. There are few case reports on the use of ibrutinib in RT. Here, we present a patient who was heavily pretreated for CLL, including allogeneic stem cell transplant, and progressed to RT. She had a mixed response to multi-agent chemotherapy and was started on ibrutinib. She had a complete response for 16 months on single-agent ibrutinib with minimal toxicity.
机译:进展为里希特转化(RT)的慢性淋巴细胞性白血病(CLL)患者预后较差。多药物化疗方案的反应率不高。关于在室温下使用依鲁替尼的病例报道很少。在这里,我们介绍了一位接受了CLL大量预处理的患者,包括同种异体干细胞移植,并进展为RT。她对多种药物的化疗反应不一,因此开始接受依鲁替尼治疗。她对单药依鲁替尼的反应完全,且毒性最小。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号